AIM ImmunoTech Inc - Company Profile
Powered by 
All the data and insights you need on AIM ImmunoTech Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AIM ImmunoTech Inc Strategy Report
- Understand AIM ImmunoTech Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
AIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various types of cancers, including ovarian, breast, colorectal, melanoma, renal cell carcinoma, pancreatic, bladder cancers, MERS and influenza virus. The company operates a production facility in New Brunswick, New Jersey. AIM ImmunoTech is headquartered in Ocala, Florida, the US.
Headquarters
United States of America
Address
2117 Sw Highway 484, Ocala, Florida, 34473-7949
Website
aimimmuno.com
Telephone
1 352 4487797
No of Employees
26
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AIM (AFM)
Revenue (2022)
$202,000
43.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-48.9%
(2022 vs 2021)
Market Cap*
$23.8M
Net Profit Margin (2022)
XYZ
-4.0%
(2022 vs 2021)
* As of and is in US$
AIM ImmunoTech Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rintatolimod - Chronic Fatigue Syndrome | Ampligen / Rintamod |
| Alferon N Injection- Refractory to Recombinant IFN | Alferon |
| Alferon N Injection- Intolerant to Recombinant IFN | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | AIM ImmunoTech Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United Kingdom |
| City | Ocala | Kenilworth | New York | Basel | Brentford |
| State/Province | Florida | New Jersey | New York | - | England |
| No. of Employees | 26 | 72,000 | 88,000 | 76,057 | 70,212 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William M. Mitchell, M.D., Ph.D. | Chairman | Executive Board | 2016 | 88 |
| Thomas K. Equels | Vice Chairman; President; Chief Executive Officer | Executive Board | 2016 | 70 |
| Robert Dickey IV | Chief Financial Officer | Senior Management | 2022 | 66 |
| Peter W. Rodino III | Secretary; Chief Operating Officer; General Counsel | Senior Management | 2019 | 71 |
| David R. Strayer, M.D | Chief Scientific Officer; Director - Medical | Senior Management | 1986 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward